Full Press Release Details
dupixent dupilumab phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria csu.
REGN
dupixent dupilumab phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria csu
Key Takeaway: dupixent dupilumab phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria csu